Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sunovion
ClinicalTrials.gov Identifier:
NCT00857220
First received: March 4, 2009
Last updated: June 18, 2013
Last verified: June 2013
  Purpose

A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.


Condition Intervention Phase
Insomnia
Attention Deficit Hyperactivity Disorder
Drug: eszopiclone
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia

Resource links provided by NLM:


Further study details as provided by Sunovion:

Primary Outcome Measures:
  • Overall Incidence of Adverse Events [ Time Frame: 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Overall Incidence of Skin Reactions: Number of Events [ Time Frame: 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: Yes ]
  • Overall Incidence of Skin Reactions: Number of Participant Affected [ Time Frame: 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: Yes ]
  • Clinical Laboratory Assessments [ Time Frame: Day -30 to -1, Day 0, Week 2(for treatment naive pts), and Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ] [ Designated as safety issue: No ]
  • Vital Sign Measurements [ Time Frame: Day -14 to -1, Day 0, Week 2, and Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 ] [ Designated as safety issue: No ]
  • Orthostatic Effects [ Time Frame: Day -14 to -1, Day 0, Week 2 (for treatment naive pts) , and Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 ] [ Designated as safety issue: No ]
  • 12 Lead ECG Parameters [ Time Frame: Day -30 to -1, and Months 1 and 12 ] [ Designated as safety issue: No ]
  • Physical Examinations [ Time Frame: Day -30 to -1, and Months 1, 3, 6, 9, and 12 ] [ Designated as safety issue: No ]
  • Neurologic Examinations [ Time Frame: Day -14 to -1, and Months 1, 3, 6, 9, and 12 ] [ Designated as safety issue: No ]
  • Columbia-Suicide Severity Rating Scale (C-SSRS) Item Responses [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    The C-SSRS is a physician-completed scale to assess any suicidal ideation and suicidal behavior. The C-SSRS contained questions about suicidal behavior and suicidal ideation. Subjects were placed into categories for suicidal behavior and for suicidal ideation based on their responses to various questions. Any suicidality was defined as suicidal behavior or suicidal ideation. The suicidal behavior categories were determined based on the response to the questions under suicidal behavior (Completed Suicide, Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior).The suicidal ideation categories were determined by examining the response to 5 questions under suicidal ideation (Wish to be Dead, Nonspecific Active Suicidal Thoughts, Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, Active Suicidal Ideation with Some Intent to Act, without Specific Plan, Active Suicidal Ideation with Specific Plan and Intent).

  • Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST)at Month 12 [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    These tests are standardized information processing tasks to assess recognition and recoding of sensory information. The subject was given 90 seconds to complete as many substitutions of symbols as possible according to a code provided on top of the sheet. The Coding Copy Subtest A was used for subjects 6 to 7 years of age, the Coding Copy Subtest B was used for subjects 8 to 16 years of age, and the DSST was used for subjects 17 years of age. The DSST consists of rows containing small blank squares, each paired with a randomly assigned numbers 1-9. Above the rows is a key that pairs each number with a symbol. The subject must fill in the blank spaces with the matching symbol that is in the key. For the Subcopy tests the subject simply copies the symbol above each empty square. Scaled scores are used to account for age differences among test takers. Scaled scores range from 1 to 19, and higher scores indicate higher cognitive function.

  • Clinical Global Impression (CGI) Improvement Score as Assessed by Parent/Caregiver or Child at Month 12 [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    A 7-point scale was used for improvement with numeric values assigned to each of the responses: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), and very much worse (7).

  • Change From Baseline at Month 12 in Subjective Sleep Latency (SL) [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    Sleep latency is the amount of time it takes to fall asleep after the lights have been turned off.

  • Change From Baseline in Child Behavior Checklist (CBCL) [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    CBCL was completed by parents or guardians who saw the child in home-like settings. It includes several competence items, open-ended items for describing the child's illnesses, disabilities, concerns about the child, best things about the child, and several items to rate behavioral, emotional, and social problems. Responses are recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The checklist contains 120 questions. The standardized score is computed by determining the z-score by subtracting the mean for the subject's age group and gender from the raw score and then dividing this by the standard deviation for the subject's age group and gender. Next, multiply the zscore by 15 and then add 100. For activities scale, social scale, school scale, and total competence scale, higher values indicate higher competencies. For Internalizing problems, externalizing problems, and total problems, higher values indicate more problems.

  • Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12 [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    The PDSS total score ranges from a low of 0 where the individual is endorsing each item at the lowest level of daytime sleepiness to a high of 32 where the individual is endorsing each item at the highest level of daytime sleepiness.

  • Change From Baseline in Conners' Continuous Performance Test II (CCPT II) [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    The CCPT-II is a computer-based 14-minute, visual-performance task. During an administration, respondents were required to press the space bar or click the mouse whenever any letter except the target letter appears on the screen. The speed at which the letters were presented varied during the administration. There were 6 blocks, with 3 sub-blocks, each containing 20 trials (letter presentations). The interstimulus intervals (ISIs) were 1, 2, and 4 seconds with a display time of 250 milliseconds. The order in which the different ISIs were presented varied between blocks. Conners' CCPT-II provides the following measures:% Omissions,% Commissions, Hit Reaction Time, Hit Reaction Time Standard Error,Variability of Standard Error, Detectability (d'), Response Style (beta), Perseverations, Hit Reaction Time Block Change (Vigilance Measure), Hit Standard Error Block Change (Vigilance Measure), Hit Reaction Time ISI change, and Hit Standard Error ISI Change, Confidence Index.

  • Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO) [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. WASO was assessed based on the responses to the sleep questionnaire.

  • Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO) [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. NAASO was assessed based on the responses to the sleep questionnaire.

  • Change From Baseline at Month 12 in Subjective Total Sleep Time (TST). [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. TST was assessed based on the responses to the sleep questionnaire.

  • Change From Baseline in Pediatric Quality of Life Scale [ Time Frame: Baseline and 12 Months (from the 1st dose to the end of study) ] [ Designated as safety issue: No ]
    The SF-10™ Health Survey for Children is a 10-item care-giver completed assessment designed to measure children's health-related quality of life. The scale asked questions about the child's physical wellness, feelings, behavior, and activities at school and with family and friends. The SF-10 physical and psychosocial summary measures were scored such that higher scores indicated more favorable functioning. The Physical Summary Score is computed by summing values for questions 1, 2a, 2b, 3 and 5 and standardizing scores by normalizing to a total possible score of 0-100 with higher scores representing more positive indications. The Psychosocial Summary Score is computed by summing questions 4, 6, 7, 8, and 9 and standardizing scores by normalizing to a total possible score of 0-100 with higher scores representing more positive indications.


Enrollment: 304
Study Start Date: May 2009
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs) Drug: eszopiclone
One 2 mg tablet per day for 12 months
Drug: eszopiclone
one 3mg tablet per day for 12 months

Detailed Description:

This is a multi center, open label, long term safety study in pediatric subjects 6 through 17 years of age, inclusive, with a diagnosis of ADHD associated insomnia. Subjects who complete Study 190 246 (Rollover subjects) and meet the study enrollment criteria will be allowed to participate in this long term safety study. Additionally, Treatment naïve subjects will be enrolled in this long term safety study in order to meet the overall subject enrollment objective of obtaining 100 subjects with 12 months of treatment. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

  Eligibility

Ages Eligible for Study:   6 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Inclusion Criteria:

  • Subject is male or female 6 17 years of age, inclusive, at the time of consent.
  • Subject must have a diagnosis of ADHD as defined by DSM-IV criteria • The diagnosis for Rollover subjects will be taken from the Screening visit of Study 190 246. Treatment naïve subjects will have these assessments performed at the Screening visit.
  • Subject must have documented ADHD associated insomnia, defined as the subject or subject's parent/legal guardian having reported repeated difficulty with sleep initiation (sleep latency >30 minutes) or consolidation (wake time after sleep onset > 45 minutes),>despite adequate age appropriate time and opportunity for sleep.
  • Subject has either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake time after sleep onset (WASO) demonstrated by PSG.
  • Subject or subject's parent/legal guardian should have reported daytime functional impairment as a result of sleep problems.
  • Subject or subject's parent/legal guardian should have reported attempted and failed behavioral interventions for sleep problems, including a regular bedtime and rise time.
  • Subject's sleep disturbance must not be attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication whether it is being used as intended or in an illicit manner.
  • Female subjects ≥8 years of age must have a negative serum pregnancy test at screening
  • Subject must be in good general health.
  • Subject must be able to swallow tablets.
  • If subjects are currently taking medication for ADHD, they must be on a stable dose and regimen for at least one month, and preferably for at least 3 months prior to the time of consent

Exclusion Criteria:

  • Subject with weight <10th percentile for age and gender
  • Subject has any clinically significant or unstable medical abnormality/illness
  • Subject has a documented history of Bipolar I or II Disorder, major depression, conduct disorder, generalized anxiety disorder (other than obsessive-compulsive disorder) or any history of psychosis, as determined by medical or psychiatric history or as determined by clinical interview using the MINI-Kid at Visit 1.
  • Subject has periodic limb movement >5 times per hour, as demonstrated on PSG.
  • Subject has sleep disordered breathing, as demonstrated on PSG.
  • Subject has another primary sleep disorder (or secondary sleep disorder that is causing clinical impairment or any other known or suspected medical or psychiatric condition that has affected or may affect sleep
  • Subject has a history of circadian rhythm disorder or will travel across ≥3 time zones more than once during the study.
  • Subject has organic brain disease, or a history of febrile seizures.
  • Subject is, in the opinion of the investigator, at suicidal or homicidal risk.
  • Female subject who is pregnant, lactating or planning to become pregnant.
  • Subject is taking any psychotropic or disallowed medications,
  • Subject has a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.
  • Subject has a history of allergic reaction or has a known or suspected sensitivity to racemic zopiclone, eszopiclone, or any substance that is contained in the formulation.
  • Subject has a history of alcohol or substance abuse within 3 months of study participation
  • Subject has participated in any investigational study within 30 days prior to study entry or is currently participating in another clinical trial, except Study 190 246.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00857220

  Show 89 Study Locations
Sponsors and Collaborators
Sunovion
  More Information

No publications provided

Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT00857220     History of Changes
Other Study ID Numbers: 190-247
Study First Received: March 4, 2009
Results First Received: November 2, 2012
Last Updated: June 18, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Sunovion:
Hypnotic
Eszopiclone
Attention Deficit Hyperactivity Disorder
Insomnia
Children
Adolescent

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Sleep Initiation and Maintenance Disorders
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Eszopiclone
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 17, 2014